Branched-chain-amino-acid aminotransferases (BCATs) are enzymes that catalyze the first reaction in the catabolism of the essential branched-chain amino acids leucine, isoleucine, and valine to their respective keto-acids while producing glutamate.
Recombinant Human BCATs are measured by their ability to convert leucine and alpha-ketoglutarate to alpha-ketoisocaproate and glutamate through an enzymatically coupled assay. Using this assay system, Recombinant Human BCAT1 (Catalog # 9536-BA; blue, left) has approximately 2X higher turnover and specific activity than BCAT2 (Catalog # 9537-BA; blue, right) as described previously. Negative controls are shown in green and red. |
There are two BCAT isozymes in humans, a mitochondrial form known as BCATm or BCAT2 and a cytosolic form known as BCATc or BCAT1. Both enzymes are regulated by redox and implicated as markers for oxidative stress linked to Alzheimer’s disease and dementia (1-3). More recently BCATc has been shown to cause cell proliferation in cancer (4-7) and was recently described as a diagnostic marker in cancers (8-10). In addition, two recent high-profile papers have linked BCAT activity to tumor metabolism and inflammatory disease (11,12). These studies suggest that BCATs may be novel drug targets for both cancer and inflammatory disorders.